Protocol Ledger

NCT06122662 · Phase II/III · COMPLETED

AMX0035 and Progressive Supranuclear Palsy

Interventional Phase II/III clinical trial protocol NCT06122662 sponsored by Amylyx Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-21 Enrollment: 139 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06122662
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)139 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06122662
Protocol FieldVerified Registry Value
NCT IdentifierNCT06122662
Consolidated Lead SponsorAmylyx Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment139 participants (ACTUAL)
Registered Start Date2023-12-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI